Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Abstract SARS‐CoV‐2 Omicron sublineages escape most preclinical/clinical neutralizing antibodies in development, suggesting that previously employed antibody screening strategies are not well suited to counteract the rapid mutation of SARS‐CoV‐2. Therefore, there is an urgent need to screen better b...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2024-12-01
|
| Seri Bilgileri: | Advanced Science |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/advs.202402975 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
